Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS/NRAS Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05593328
What this trial is testing

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Who this might be right for
Colorectal CancerMetastatic Colorectal Cancer
Cardiff Oncology 23
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Testing effectiveness (Phase 2)Active Not RecruitingNCT06106308
What this trial is testing

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Who this might be right for
Metastatic Colorectal CancerCRCKRAS/NRAS Mutation
Cardiff Oncology 110
Testing effectiveness (Phase 2)UnknownNCT03693326
What this trial is testing

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Who this might be right for
CancerLung Cancer MetastaticImmunotherapy
Asan Medical Center 70
Testing effectiveness (Phase 2)Study completedNCT01704703
What this trial is testing

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

Who this might be right for
Stage IV Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 72
Large-scale testing (Phase 3)Looking for participantsNCT06881784
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more
Revolution Medicines, Inc. 590
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71
Large-scale testing (Phase 3)Looking for participantsNCT07491445
What this trial is testing

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more
Revolution Medicines, Inc. 900
Early research (Phase 1)Study completedNCT02729298
What this trial is testing

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more
Sumitomo Pharma America, Inc. 177
Early research (Phase 1)Study completedNCT03597581
What this trial is testing

RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Who this might be right for
Gastrointestinal CancerGastrointestinal NeoplasmsColorectal Cancer+7 more
Inspirna, Inc. 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864
What this trial is testing

ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more
Elicio Therapeutics 158
Early research (Phase 1)Looking for participantsNCT06096974
What this trial is testing

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Who this might be right for
Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd. 60
Not applicableStudy completedNCT03750175
What this trial is testing

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

Who this might be right for
Colorectal Cancer MetastaticCirculating Tumor DNAKRAS Gene Mutation+3 more
Karen-Lise Garm Spindler 49
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Testing effectiveness (Phase 2)Temporarily pausedNCT06876142
What this trial is testing

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 54
Not applicableLooking for participantsNCT06449989
What this trial is testing

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

Who this might be right for
Colorectal Cancer MetastaticBrain Metastases, AdultRas (KRAS or NRAS) Gene Mutation+3 more
Blokhin's Russian Cancer Research Center 30
Early research (Phase 1)Looking for participantsNCT06326411
What this trial is testing

Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Who this might be right for
OncologyMEK MutationRAF Gene Mutation+6 more
Nested Therapeutics, Inc 230
Large-scale testing (Phase 3)Study completedNCT02394795
What this trial is testing

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Who this might be right for
Colorectal Cancer
Takeda 823
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Ended earlyNCT03745326
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Gastrointestinal CancerPancreatic CancerGastric Cancer+2 more
National Cancer Institute (NCI) 5
Next Page